MC2 Therapeutics aims to lead psoriasis market

Psoriasis drug Wynzora brings MC2 Therapeutics one step closer to achieving its goal of becoming world-leading within drugs applied onto skin, says MC2 Therapeutics CEO Jesper Lange.
MC2 Therapeutics CEO Jesper Lange | Photo: MC2 Therapeutics / PR
MC2 Therapeutics CEO Jesper Lange | Photo: MC2 Therapeutics / PR
BY ANDREAS LØNSTRUP, TRANSLATED BY NIELSINE NIELSEN

Danish pharmaceutical company MC2, which is owned by family members behind major Danish companies Danfoss and Radiometer, dreams of becoming world-leading in drugs applied to the skin. The first step towards reaching this goal includes psoriasis drug Wynzora, which has been approved by the US Food and Drug Administration and is being launched in the US, and which awaits Europe approval in summer, according to Danish newspaper Børsen.

Already a subscriber?Log in here

Read the whole article

Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

With your free trial you get:

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
Must be at least 8 characters, including three of: Uppercase, lowercase, numbers, symbols
Must contain at least 2 characters
Must contain at least 2 characters

Get full access for you and your coworkers

Start a free company trial today

Share article

Sign up for our newsletter

Stay ahead of development by receiving our newsletter on the latest sector knowledge.

Newsletter terms

Front page now

Further reading